RCT: Subcutaneous Tirzepatide added to titrated Insulin Glargine improves glycemic control in patients with Type 2 Diabetes.

Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial – JAMA (free for a limited period)

Editorial: Tirzepatide for Patients With Type 2 Diabetes – JAMA

Commentary: SURPASS-5 Data: Tirzepatide Plus Insulin Glargine Improve Glycemic Control in T2D – AJMC

Related:

RCT: In patients with Type 2 Diabetes, Tirzepatide is associated with reduced weight, improved glycemic control, and lower risk of hypoglycemia compared to insulin glargine.

RCT: Once-weekly tirzepatide vs. once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes.

RCT: Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2.

RCT: Tirzepatide yielded greater glycated hemoglobin and body weight reductions compared to Semaglutide 1 mg.